FDA Approves First in Class Tx for Myelosuppression in SCLC – Cosela
Earlier this month the FDA approved another infused specialty therapy, Cosela (trilaciclib) from G1 Therapeutics. It is the first therapy in its class to reduce
February 25, 2021
Earlier this month the FDA approved another infused specialty therapy, Cosela (trilaciclib) from G1 Therapeutics. It is the first therapy in its class to reduce
As readers of the AntonRx Report may know, we scan hundreds of articles each week to sleuth out information that is timely and important to
Last week the FDA approved yet another uber expensive therapy, Evkeeza from Regeneron Pharmaceuticals, to treat homozygous familial hypercholesterolemia (HoFH), an ultra-rare inherited condition that
Earlier this month the FDA approved a new ORAL therapy, Tepmetko (tepotinib) from EMD Serono, for the treatment of naïve and previously treated patients with
This week the FDA approved a new ORAL therapy, Ukoniq (umbralisib) from TG Therapeutics with indications for marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Specialty pharmacies won’t be dispensing Breyanzi, approved by the FDA last week for the treatment of late-stage lymphoma with certain types of large B-cell lymphoma
During 2020 we saw a measurable uptick in the number of FDA approved therapies that were LD-DTO….. which you should know stands for Limited Distribution,
The FDA has approved a new, first ever therapy for Lupus nephritis, Lupkynis (voclosporin) from Aurinia Pharmaceuticals, in combination with background immunosuppressive therapy. It is
The 340b program is once again in the news. All the wailing and gnashing of teeth over recent years boiled over on 2020 with a
Last week the FDA approved a new specialty therapy for adult HIV positive patients. Be patient, it will take some time to explain this announcement
